REVBIO IS POISED TO LAUNCH THE MARKET’S FIRST AND ONLY PATENTED SYNTHETIC BIOADHESIVE
RevBio is a clinical stage medical device company engaged in the development and commercialization of Tetranite, a patented, synthetic, injectable, self-setting, load-bearing, and osteoconductive bone adhesive biomaterial that bonds bone to bone and bone to metal. The company is initially developing this technology for use in the dental market, and recently initiated its first-in-man clinical study for the use of Tetranite to immediately stabilize dental implants in sites that lack sufficient primary stability. RevBio is also working to develop adhesive applications for the broader orthopaedics market.
THIS TECHNOLOGY IS PROTECTED BY MULTIPLE FAMILIES OF U.S. AND WORLDWIDE PATENTS
RevBio has rights to multiple patents directed to the Tetranite technology. RevBio is also actively pursuing patent protection for additional compositions, as well as specific methods for its use.
REVBIO PARTNERS WITH LEADING RESEARCH INSTITUTIONS AND UNIVERSITIES
RevBio has developed a broad base of research partners and collaborators for the development of indication-specific products based on the Tetranite technology. These partners and collaborators include experienced university-based research teams and leading clinical research organizations.
OUR Facilities ARE STATE OF THE ART
RevBio operates out the Massachusetts Medical Device Development Center (M2D2), a technology incubator focused on fostering the development of cutting-edge medical device technologies like Tetranite. The company has a dedicated laboratory suite where it conducts its product development, quality control, and manufacturing activities. Since M2D2 is located on the Lowell Campus of the University of Massachusetts, RevBio has access to a vast domain of equipment and expertise within the UMass core research facilities.
REVBIO HAS RECEIVED MULTIPLE GRANTS FROM LEADING INSTITUTIONS VALIDATING ITS TECHNOLOGY
RevBio has received in excess of $9 million in grant funding from the National Institutes of Health, NASA, private foundations, and the U.S. Department of Defense. Some of these grants include the following:
| GRANT TOPIC | DESCRIPTION |
|---|---|
| Bioadhesive Mechanism of Action (NIH STTR Phase I) | The proceeds of this grant were used to examine structural properties and mechanism of action of the bioadhesive properties of Tetranite. |
| Dental Implant Stabilization (Private Foundation) | A grant to conduct a pivotal animal study to examine the efficacy and safety of immediate stabilizing dental implants in unstable sites where primary stability is not achievable. |
| Osteoblastic Activity in Low Gravity (CASIS/BOEING/NASA) | This grant funded an in vitro experiment on the International Space Station to examine the effects of Tetranite on osteoblastic cells and the material’s osteoconductive capacity. |
| Dental Bone Grafting (Michigan-Pittsburgh-Wyss Regenerative Medicine Center) | Three successive grants for the development of a dental bone graft product based on the Tetranite technology that does not require ancillary containment (membranes or meshes) and fixation aids (tacks or screws) like most other graft materials. |
| Dental Drug Delivery (NIH SBIR Phase I) | Funds to develop a Tetranite-anesthetic formulation to eliminate post-operative opioid prescriptions following outpatient wisdom teeth extraction surgery. |
| Cranial Flap Fixation (NIH SBIR Direct-to-Phase II) | Grant for completing the development of a Tetranite-based product for repairing cranial defects without the use of conventional hardware in order to reduce the potential for cerebrospinal fluid leads and related infections. |
| Treatment of Wrist Fractures (NIH SBIR Phase II) | In partnership with the National Institute on Aging, this grant will allow the company to pursue the treatment of wrist fractures with its patented bone adhesive technology known as Tetranite®. |
Treatment of Vertebral Compression Fractures (NIH SBIR Phase I) | This Grant will Advance the Company’s Pre-Clinical Research to Demonstrate an Improvement to the Current Standard of Care for Spine Fractures. |